Home » Stocks » XBIO

Xenetic Biosciences, Inc. (XBIO)

Stock Price: $2.76 USD 0.04 (1.47%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Pre-market: $2.75 -0.01 (-0.36%) Jan 20, 8:02 AM
Market Cap 24.57M
Revenue (ttm) 302,676
Net Income (ttm) -10.86M
Shares Out 6.30M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $2.76
Previous Close $2.72
Change ($) 0.04
Change (%) 1.47%
Day's Open 2.73
Day's Range 2.66 - 2.85
Day's Volume 549,289
52-Week Range 0.49 - 3.17


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Accesswire - 6 days ago

FRAMINGHAM, MA / ACCESSWIRE / January 14, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized C...

Accesswire - 2 weeks ago

FRAMINGHAM, MA / ACCESSWIRE / January 5, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CA...

Benzinga - 1 month ago

Shares of Xenetic Biosciences Inc (NASDAQ: XBIO), a drug delivery platform company, were ripping higher Wednesday on markedly above-average volume. What Happened: The Framingham, Massachusetts...

Market Watch - 1 month ago

Shares of Xenetic Biosciences Inc. skyrocketed on massive volume toward a 17-month high in morning trading Wednesday, after the Massachusetts-based biopharmaceutical company said its partner P...

Pulse2 - 1 month ago

The stock price of Xenetic Biosciences, Inc. (NASDAQ:XBIO) are trading at over 300% as it went from $1.08 in the previous close to $4.88 as of 11:17 AM ET. This is why it happened.

InvestorPlace - 1 month ago

Xenetic Biosciences (XBIO) news for Wednesday includes positive news from a Phase 3 clinical trial boosting XBIO stock higher. The post Xenetic Biosciences News: Why XBIO Stock Is Going Ballis...

Benzinga - 1 year ago

Nano-cap biotech Xenetic Biosciences Inc.'s stock was rallying Friday following an announcement concerning pricing for its previously announced offering of common stock and accompanying warrants.

About XBIO

Xenetic Biosciences, a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and novel oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary... [Read more...]

Jeffrey F. Eisenberg
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for XBIO stock is "Buy." The 12-month stock price forecast is 3.75, which is an increase of 35.87% from the latest price.

Price Target
(35.87% upside)
Analyst Consensus: Buy